BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Week In Review | Sep 19, 2016
Clinical News

Omega-3 phospholipids: Bridging study data

An open-label, 4-way crossover bridging study in 56 healthy volunteers showed that a single dose of 4 g oral CaPre met the primary endpoint based on EPA and DHA levels. Specifically, levels of EPA and...
BC Week In Review | Nov 3, 2014
Clinical News

Omega-3 phospholipids: Phase II data

Top-line data from the double-blind, Canadian Phase II TRIFECTA trial in 365 evaluable patients with mild to severe hypertriglyceridemia showed that once-daily 1 and 2 g CaPre each met the primary endpoint of reducing mean...
BC Week In Review | May 5, 2014
Company News

Acasti, Enzymotec, Neptune Technologies nutraceuticals news

The companies reached a settlement agreement related to Neptune's patents for marine omega-3 phospholipids , ending an International Trade Commission (ITC) investigation and ongoing suit in U.S. court. Enzymotec received a non-exclusive, worldwide license to Neptune's...
BC Week In Review | Sep 2, 2013
Clinical News

CaPre omega-3 phospholipids: Phase II data

An open-label, dose-escalation, Canadian Phase II trial in over 230 patients showed that 4 g once-daily CaPre led to a significant reduction in mean triglyceride levels of 15.5% from baseline to week 4, which was...
BC Week In Review | Jul 29, 2013
Company News

Acasti, Neptune Technologies deal

Acasti prepaid its parent company Neptune about C$15.5 million ($15 million) in stock for royalties Neptune was eligible to receive under a 2008 deal granting its subsidiary rights to develop new APIs based on Neptune's...
BioCentury | Jul 1, 2013
Product Development

POC for APOCIIIRx

If initial Phase II data bear out in larger trials, Isis Pharmaceuticals Inc. thinks ISIS-APOCIIIRx could alter the treatment landscape for hypertriglyceridemia much like statins did for hypercholesterolemia. ISIS-APOCIIIRx is an antisense inhibitor of apolipoprotein...
BC Week In Review | Jan 7, 2013
Clinical News

CaPre omega-3 phospholipids: Phase II ongoing

On Dec. 17, 2012, Acasti said an independent review committee recommended continuation of the double-blind, placebo-controlled, Canadian Phase II TRIFECTA trial of CaPre based on an interim analysis of safety and efficacy data. The trial...
BC Week In Review | Jan 7, 2013
Clinical News

CaPre omega-3 phospholipids: Phase II amended

On Dec. 17, 2012, Acasti said it amended an open-label, dose-escalation, Canadian Phase II trial of 0.5, 1 and 2 g CaPre daily for 8 weeks to include 4 g CaPre daily following FDA's recommendation....
BC Week In Review | Dec 12, 2011
Clinical News

CaPre omega-3 phospholipids: Phase II started

Neptune's Acasti Pharma Inc. subsidiary began an open-label, Canadian Phase II trial evaluating CaPre in about 174 patients with moderately high to very high levels of triglycerides. Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX:NTB), Laval,...
Items per page:
1 - 10 of 16